Eplerenone reduces morbidity and mortality after acute MI.
D000208:Acute Disease; D004311:Double-Blind Method; D000077545:Eplerenone; D007172:Erectile Dysfunction / Q000139:chemically induced; D005260:Female; D006177:Gynecomastia / Q000139:chemically induced; D006333:Heart Failure / Q000188:drug therapy / Q000209:etiology / Q000401:mortality; D006760:Hospitalization; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000401:mortality*; D013148:Spironolactone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000401:mortality
D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000077545:Eplerenone